LY-293558. Eli Lilly & Co.

Abstract

Lilly is developing the racemic compound LY-215490, a selective and competitive AMPA antagonist, as a potential treatment for cerebral infarction, cerebrovascular ischemia, epilepsy and as an analgesic [135089], [158980], [254029], [278691]. By January 2000, LY-293558 was undergoing phase II trials for pain [414000].

• Authors: I Gilron
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 9 Pg. 1273-8 (Sep 2001) ISSN: 1472-4472 [Print] England
• PMID: 11717815 (Publication Type: Journal Article, Review)

Chemical References

• Excitatory Amino Acid Antagonists
• Isoquinolines
• Receptors, AMPA
• Tetrazoles
• tezampanel

Topics

• Animals
• Cerebrovascular Disorders (drug therapy)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Contraindications
• Excitatory Amino Acid Antagonists (adverse effects, metabolism, pharmacology, therapeutic use)
• Humans
• Isoquinolines (adverse effects, metabolism, pharmacology, therapeutic use)
• Pain (drug therapy)
• Receptors, AMPA (antagonists & inhibitors)
• Structure-Activity Relationship
• Tetrazoles (adverse effects, metabolism, pharmacology, therapeutic use)